达格列净对射血分数降低心衰患者高敏肌钙蛋白动态变化的影响:DAPA-HF 试验分析
基于 DAPA-HF 随机双盲安慰剂对照试验,在 3112 例射血分数降低心衰患者中基线测量高敏肌钙蛋白 T(hsTnT),2506 例于 1 年时复测。基线 hsTnT 越高及 1 年内相对或绝对升高均与更差临床结局相关;达格列净在各基线 hsTnT 四分位组中一致降低主要终点风险,并倾向于减缓 hsTnT 随时间升高。
要点
- 基线 hsTnT 越高,主要终点风险逐级升高(Q4 对 Q1 校正 HR 3.44)。
- 1 年内 hsTnT 相对或绝对升高与后续主要终点风险增高相关。
- 达格列净降低主要终点的相对效应在各基线 hsTnT 四分位组中一致。
核心结论
- 基线 hsTnT 越高及 1 年内升高幅度越大与更差临床结局相关,达格列净在各基线 hsTnT 水平下均一致降低主要终点风险。
研究设计与样本
- DAPA-HF 为随机双盲安慰剂对照试验,纳入 NYHA II–IV 级、LVEF ≤40% 的患者,达格列净 10 mg 每日一次,中位随访 18.2 个月。
- 基线 hsTnT 测量 3112 例,1 年时测量 2506 例,采用 Roche Diagnostics 检测。
主要发现
- 基线 hsTnT 中位数 20.0 ng/L(25–75 百分位 13.7–30.2)。
- 1 年内 67.9% 患者 hsTnT 相对变化≥10%,43.5% 相对变化≥20%。
- 基线 hsTnT 四分位组间主要终点风险呈阶梯式升高,Q4 对 Q1 校正 HR 3.44(95% CI 2.46–4.82)。
- 1 年内 hsTnT 相对和绝对升高与后续主要终点风险增高相关。
- 达格列净相对风险降低在各基线 hsTnT 四分位组中一致(P-interaction=0.55),最高四分位组绝对风险差 7.5%(95% CI 1.0%–14.0%)。
临床怎么用
- 基线及随访 hsTnT 可用于心衰风险分层,动态升高提示预后更差。
- 无论基线 hsTnT 水平如何,达格列净均可一致降低主要终点风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating high-sensitivity cardiac troponin T (hsTnT) predominantly reflects myocardial injury, and higher levels are associated with a higher risk of worsening heart failure and death in patients with heart failure with reduced ejection fraction. Less is known about the prognostic significance of changes in hsTnT over time, the effects of dapagliflozin on clinical outcomes in relation to baseline hsTnT levels, and the effect of dapagliflozin on hsTnT levels. METHODS: DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure) was a randomized, double-blind, placebo-controlled trial of dapagliflozin (10 mg daily) in patients with New York Heart Association class II to IV symptoms and left ventricular ejection fraction ≤40% (median follow-up, 18.2 months). hsTnT (Roche Diagnostics) was measured at baseline in 3112 patients and at 1 year in 2506 patients. The primary end point was adjudicated worsening heart failure or cardiovascular death. Clinical end points were analyzed according to baseline hsTnT and change in hsTnT from baseline to 1 year. Comparative treatment effects on clinical end points with dapagliflozin versus placebo were assessed by baseline hsTnT. The effect of dapagliflozin on hsTnT was explored. RESULTS: Median baseline hsTnT concentration was 20.0 (25th-75th percentile, 13.7-30.2) ng/L. Over 1 year, 67.9% of patients had a ≥10% relative increase or decrease in hsTnT concentrations, and 43.5% had a ≥20% relative change. A stepwise gradient of higher risk for the primary end point was observed across increasing quartiles of baseline hsTnT concentration (adjusted hazard ratio Q4 versus Q1, 3.44 [95% CI, 2.46-4.82]). Relative and absolute increases in hsTnT over 1 year were associated with higher subsequent risk of the primary end point. The relative reduction in the primary end point with dapagliflozin was consistent across quartiles of baseline hsTnT (P-interaction=0.55), but patients in the top quartile tended to have the greatest absolute risk reduction (absolute risk difference, 7.5% [95% CI, 1.0%-14.0%]). Dapagliflozin tended to attenuate the increase in hsTnT over time compared with placebo (relative least squares mean reduction, -3% [-6% to 0%]; P=0.076). CONCLUSIONS: Higher baseline hsTnT and greater increase in hsTnT over 1 year are associated with worse clinical outcomes. Dapagliflozin consistently reduced the risk of the primary end point, irrespective of baseline hsTnT levels. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
引用
- Berg DD, Docherty KF, Sattar N, et al. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 2021. PMID: 34743554. doi:10.1161/CIRCULATIONAHA.121.057852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。